Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.
Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.
Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.
Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) reported a 25% year-over-year increase in sales of its FastPack diagnostics for Q3 2022, totaling $1.4 million. The company's net loss was approximately $4.1 million, consistent with the prior year. R&D costs decreased to $1.7 million as the company shifts focus from COVID-19 to its core therapeutics pipeline. Significant progress was noted in preclinical data for QN-302 and QN-247. Shareholders approved a reverse stock split to comply with Nasdaq listing requirements. Cash reserves stand at $6.6 million, expected to fund operations through Q3 2023.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) presented preclinical data on its RAS-targeted platform at the Fourth RAS Initiative Symposium held from October 17-19, 2022. The company is focused on developing treatments for cancers driven by RAS oncogenes. Two key posters highlighted the efficacy of its lead candidate, RAS-F, which demonstrated the potential to inhibit tumor growth in malignant peripheral nerve sheath tumors and pancreatic cancer. Qualigen aims to address the unmet need for more effective RAS-targeted therapies, as current options are limited.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced that President Amy Broidrick and Chief Medical Officer Tariq Arshad, MD, will present a corporate overview at the LD Micro Main Event XV from October 25-27, 2022. The presentation is scheduled for October 26 at 12:30 PM PT. Attendees can view the livestream by registering online. Qualigen focuses on developing treatments for adult and pediatric cancers and offers diagnostic solutions. Their investigational compounds, including QN-302 and QN-247, aim to inhibit cancer cell proliferation.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced the acceptance of two abstracts for presentation at the Fourth RAS Initiative Symposium, occurring from October 17-19, 2022, in Frederick, Maryland. The research focuses on their RAS-Targeted platform, conducted with the University of Louisville. The first presentation, on a pan-RAS inhibitor for Malignant Peripheral Nerve Sheath Tumors, is scheduled for October 17, 2022. The second, discussing a RAS inhibitor for Pancreatic Cancer, will be presented on October 18, 2022.
Qualigen Therapeutics (Nasdaq: QLGN) presented two posters showcasing its lead compound QN-302 at the AACR 8th Special Conference on Pancreatic Cancer in Boston from September 13-16, 2022. The posters highlighted QN-302's safety profile, showing no cardiac or neurological liabilities in preclinical mouse models, and its potential to target the S100P gene, which may aid in pancreatic cancer treatment. The company is on track to file an Investigational New Drug application in the first half of 2023, aiming for Orphan Drug Designation.
Qualigen Therapeutics (Nasdaq: QLGN) has established a Scientific Advisory Board (SAB) to advance its lead therapeutic candidate, QN-302, aimed at treating pancreatic cancer and other solid tumors. The SAB comprises top experts from notable institutions, providing strategic guidance amidst ongoing drug development efforts. CEO Michael Poirier expressed confidence in QN-302's potential, underlining the SAB's expertise as critical for the program. Qualigen specializes in cancer therapies and diagnostics, maintaining a strong research and development focus while pursuing Orphan Drug Designation.
Qualigen Therapeutics reported strong Q2 2022 results, with FastPack sales increasing by 28% year-over-year and gross profit rising 64%. Revenues reached $1.4 million, up from $1.1 million in Q2 2021. The company achieved key milestones in its oncology programs and acquired a majority stake in NanoSynex. Despite a net loss of $4.1 million, down from $5.4 million the previous year, R&D costs decreased significantly from $4.5 million to $1.5 million, indicating improved cost management. Qualigen expects its cash reserves of $9.7 million to sustain operations into 2023.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced the completion of its in vivo efficacy analysis for QN-247 in solid tumors, specifically in a model for triple negative breast cancer (TNBC). The results indicate robust efficacy and no safety concerns, leading the company to pursue further investigations. Qualigen plans to submit an IND for its QN-302 program targeting G-Quadruplex expressing solid tumors in the coming months. CEO Michael Poirier confirmed the company's strong cash position and readiness to raise capital as needed.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) has partnered with Hande Sciences to scale up manufacturing for its lead therapeutic program, QN-302, aimed at treating pancreatic cancer and other tumors. The collaboration will support IND-enabling GLP studies expected to start in Q3 2022. Hande Sciences is known for its expertise in custom synthesis and GMP manufacturing, with a facility expected to be operational by August 2022. QN-302 is a G-quadruplex-selective transcription inhibitor, potentially qualifying for Orphan Drug Designation due to pancreatic cancer's low prevalence.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) has announced its participation at the BIO International Convention taking place from June 13 to 16, 2022, at the San Diego Convention Center. The company's Chief Medical Officer, Tariq Arshad, will present an overview of its oncology drug pipeline and diagnostics business on June 15 at 2:30 PM PT. Qualigen focuses on developing cancer treatments and commercializing diagnostics, including investigational compounds QN-302 and QN-247, aimed at combating various cancers.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
